A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer · EGFR Exon 20 Mutation
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Oct 2025, none posted yet
Counts until it's fixed
Score over time
- Stage
- Phase 1/2
- Patients
- 284 (planned)
- Started
- Oct 31, 2019
- Main results expected
- Oct 13, 2025
- Fully finished
- Mar 31, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
All Cohorts: The rate and severity of treatment emergent AEs.
Measured over: 24 months
All Cohorts: The rate and severity of DLTs.
Measured over: 24 months
Phase 2 Dose Expansion Cohorts: Overall response rate (ORR)
Measured over: 24 months
Module A: Pharmacokinetic (PK) parameter
Measured over: 24 months
Module A: Pharmacokinetic (PK) parameter
Measured over: 24 months
Module B and C: Confirmed overall response rate (ORR) and duration of response (DOR) by independent review committee (IRC)
Measured over: 24 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-10-13, no fading
Raw record changes
- none yet
Trial ID NCT04036682 · record last updated 2026-06-17 · checked 2026-11-09 15:42 UTC